Literature DB >> 20538349

The risk of relapse after a clinically isolated syndrome is related to the pattern of oligoclonal bands.

I Boscá1, M J Magraner, F Coret, J C Alvarez-Cermeño, M Simó-Castelló, L M Villar, B Casanova.   

Abstract

We prospectively assessed the risk of second relapse in 192 patients with clinically isolated syndromes (CIS) divided into three groups: patients lacking oligoclonal IgG bands (OC-IgG, 25.7%), those showing OC-IgG (52.4%), and those with both OC-IgG and lipid-specific IgM bands (LS-OC-IgM, 22%). OC-IgG increased 9.3-fold the risk compared to lacking OC-IgG; OC-IgG+LS-OC-IgM increased the risk 39.6-fold compared to not having OC-IgG and 4.4-fold compared to having only OC-IgG. Median time to second relapse was 0.7 years for patients with OC-IgG+LS-OC-IgM and 3.3 years for those with only OC-IgG. Therefore, CSF analysis identifies CIS patients at risk of second relapse.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538349     DOI: 10.1016/j.jneuroim.2010.05.032

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  13 in total

1.  Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?

Authors:  Jessica Frau; Luisa Maria Villar; Claudia Sardu; Maria Antonietta Secci; Lucia Schirru; Diana Ferraro; Giancarlo Coghe; Lorena Lorefice; Giuseppe Fenu; Roberta Bedin; Patrizia Sola; Maria Giovanna Marrosu; Eleonora Cocco
Journal:  J Neurol       Date:  2017-12-22       Impact factor: 4.849

2.  Cerebrospinal fluid anti-Epstein-Barr virus specific oligoclonal IgM and IgG bands in patients with clinically isolated and Guillain-Barré syndrome.

Authors:  Diana Ferraro; Veronica Galli; Anna Maria Simone; Roberta Bedin; Francesca Vitetta; Elisa Merelli; Paolo Frigio Nichelli; Patrizia Sola
Journal:  J Neurovirol       Date:  2016-11-22       Impact factor: 2.643

3.  Brain atrophy and lesion load are related to CSF lipid-specific IgM oligoclonal bands in clinically isolated syndromes.

Authors:  Maria José Magraner; Isabel Bosca; Maria Simó-Castelló; Gracian García-Martí; Angel Alberich-Bayarri; Francisco Coret; Jose C Alvarez-Cermeño; Luís Martí-Bonmatí; Luisa M Villar; Bonaventura Casanova
Journal:  Neuroradiology       Date:  2011-02-16       Impact factor: 2.804

Review 4.  The immunopathophysiology of multiple sclerosis.

Authors:  Gregory F Wu; Enrique Alvarez
Journal:  Neurol Clin       Date:  2011-05       Impact factor: 3.806

Review 5.  From the prodromal stage of multiple sclerosis to disease prevention.

Authors:  Ruth Ann Marrie; Mark Allegretta; Lisa F Barcellos; Bruce Bebo; Peter A Calabresi; Jorge Correale; Benjamin Davis; Philip L De Jager; Christiane Gasperi; Carla Greenbaum; Anne Helme; Bernhard Hemmer; Pamela Kanellis; Walter Kostich; Douglas Landsman; Christine Lebrun-Frenay; Naila Makhani; Kassandra L Munger; Darin T Okuda; Daniel Ontaneda; Ronald B Postuma; Jacqueline A Quandt; Sharon Roman; Shiv Saidha; Maria Pia Sormani; Jon Strum; Pamela Valentine; Clare Walton; Kathleen M Zackowski; Yinshan Zhao; Helen Tremlett
Journal:  Nat Rev Neurol       Date:  2022-07-15       Impact factor: 44.711

6.  The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).

Authors:  Johannes Brettschneider; Anne Czerwoniak; Makbule Senel; Lubin Fang; Jan Kassubek; Elmar Pinkhardt; Florian Lauda; Tamara Kapfer; Sarah Jesse; Vera Lehmensiek; Albert C Ludolph; Markus Otto; Hayrettin Tumani
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

7.  Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics.

Authors:  Oscar G Vidaurre; Jeffery D Haines; Ilana Katz Sand; Kadidia P Adula; Jimmy L Huynh; Corey A McGraw; Fan Zhang; Merina Varghese; Elias Sotirchos; Pavan Bhargava; Veera Venkata Ratnam Bandaru; Giulio Pasinetti; Weijia Zhang; Matilde Inglese; Peter A Calabresi; Gang Wu; Aaron E Miller; Norman J Haughey; Fred D Lublin; Patrizia Casaccia
Journal:  Brain       Date:  2014-06-03       Impact factor: 13.501

8.  Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study.

Authors:  Carmen Alcalá; F Gascón; F Pérez-Miralles; S Gil-Perotín; A Navarré; I Boscá; F Coret; B Casanova
Journal:  J Neurol       Date:  2018-05-21       Impact factor: 6.682

9.  Predicting Aggressive Multiple Sclerosis With Intrathecal IgM Synthesis Among Patients With a Clinically Isolated Syndrome.

Authors:  Enric Monreal; Susana Sainz de la Maza; Lucienne Costa-Frossard; Paulette Walo-Delgado; Javier Zamora; José Ignacio Fernández-Velasco; Noelia Villarrubia; Mercedes Espiño; Daniel Lourido; Paloma Lapuente; Inmaculada Toboso; José Carlos Álvarez-Cermeño; Jaime Masjuan; Luisa María Villar
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-07-22

10.  Cerebrospinal fluid immunoglobulin kappa light chain in clinically isolated syndrome and multiple sclerosis.

Authors:  Makbule Senel; Hayrettin Tumani; Florian Lauda; Stefan Presslauer; Rehaneh Mojib-Yezdani; Markus Otto; Johannes Brettschneider
Journal:  PLoS One       Date:  2014-04-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.